Title: Risk of Severe COVID-19 and Mortality in Patients with Established Chronic Liver
Disease: A Nationwide Matched Cohort Study
Version: 3 Date: 04 Jun 2021
Reviewer's report:
The findings of this population based study (risk of severe COVID-19 / mortality due to
COVID-19 in CLD patients was not different from that in the general population) are different
from a number of hospital based studies, wherein patients with cirrhosis and COVID-19 had
higher mortality rates compared to controls.
I have the following comments:
1. Did any study patients die due to therapeutic limitation (ie. was death due to lack of availability
of ICU beds)
2. Did any study patient in the control arm have chronic liver disease mentioned as a co-
morbidity.
Title: Risk of Severe COVID-19 and Mortality in Patients with Established Chronic Liver
Disease: A Nationwide Matched Cohort Study
Version: 3 Date: 04 Jun 2021
Reviewer's report:
The findings of this population based study (risk of severe COVID-19 / mortality due to
COVID-19 in CLD patients was not different from that in the general population) are different
from a number of hospital based studies, wherein patients with cirrhosis and COVID-19 had
higher mortality rates compared to controls.
I have the following comments:
1. Did any study patients die due to therapeutic limitation (ie. was death due to lack of availability
of ICU beds)
2. Did any study patient in the control arm have chronic liver disease mentioned as a co-
morbidity.
Please review this paper.
user
Title: Risk of Severe COVID-19 and Mortality in Patients with Established Chronic Liver
Disease: A Nationwide Matched Cohort Study
Version: 3 Date: 04 Jun 2021
Reviewer's report:
The findings of this population based study (risk of severe COVID-19 / mortality due to
COVID-19 in CLD patients was not different from that in the general population) are different
from a number of hospital based studies, wherein patients with cirrhosis and COVID-19 had
higher mortality rates compared to controls.
I have the following comments:
1. Did any study patients die due to therapeutic limitation (ie. was death due to lack of availability
of ICU beds)
2. Did any study patient in the control arm have chronic liver disease mentioned as a co-
morbidity.
assistant